Clearside Biomedical, Inc.
CLSDQ evidence brief
What we can confirm
- BioSniper Score:
- 2.0 / 10
- Market Cap:
- $1.3M
- Next Catalyst:
- Patent_Expiry · Apr 16, 2040
What it means
What to watch
Prepared research question
What matters most for CLSDQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLSDQ
Clearside Biomedical, Inc. (CLSDQ) is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases, with one approved product (XIPERE) and a pipeline of suprachoroidal injection candidates.
Key risk: Low cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2025.
Tracking 14 clinical trials · 1 catalyst for Clearside Biomedical, Inc..
Clearside Biomedical, Inc. (CLSDQ) is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases, with one approved product (XIPERE) and a pipeline of suprachoroidal injection candidates.
- Cash and equivalents of $6.8M as of 2025-09-30 [sec].
- Total revenue of $0.2M and net loss of -$6.0M for the period ending 2025-09-30 [sec].
- Shareholders' equity of -$54.0M as of 2025-09-30 [sec].
- Approved product XIPERE (triamcinolone acetonide) for macular edema associated with uveitis, partnered with Bausch + Lomb and Arctic Vision [pipeline].
- Phase 2b trial (ODYSSEY) of suprachoroidally administered CLS-AX in neovascular age-related macular degeneration started 2023-05-31 [catalyst].
What works
- Has one approved product (XIPERE) for macular edema associated with uveitis, providing a commercial foothold [pipeline].
- Partnerships with Bausch + Lomb and Arctic Vision (licensee for multiple Asian territories) may expand market reach [pipeline].
- Pipeline includes a Phase 2b trial (ODYSSEY) of CLS-AX for neovascular age-related macular degeneration, a large-market indication [catalyst].
What to weigh
- Very low cash position ($6.8M as of 2025-09-30) and negative shareholders' equity (-$54.0M) indicate financial strain [sec].
- Minimal revenue ($0.2M) and a net loss of -$6.0M for the period ending 2025-09-30 suggest limited near-term profitability [sec].
- The approved product XIPERE faces patent expiry on 2040-04-16, which could eventually open the door to generic competition [catalyst].
From the filings
Quoted directly from source documents.
XIPERE is approved for macular edema associated with uveitis
“Indication: Macular edema associated with uveitis Phase: Approved”
Pipeline
Catalyst timeline
- 2040-04-16 · Patent_Expiry · TRIAMCINOLONE ACETONIDE — Patent_Expiry: NDA211950 — The patent for XIPERE (triamcinolone acetonide) expires, which could allow generic versions to enter the market.
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash of $6.8M as of 2025-09-30 may be insufficient to fund operations and pipeline without additional financing [sec].
- Negative equity
- Patent expiry risk — XIPERE patent expires 2040-04-16, potentially allowing generic competition [catalyst].
What to watch
- Progress of the Phase 2b ODYSSEY trial for CLS-AX in neovascular AMD, started 2023-05-31 [catalyst].
- Cash burn rate and any new financing or partnership deals to extend runway [sec].
- Commercial uptake of XIPERE and revenue growth from existing partnerships [pipeline].
Sources: Catalysts · Competitor trials · Pipeline · Generated October 4, 2026 · How we verify sources →
Run Clearside Biomedical, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Clearside Biomedical, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$6M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~4933d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$8K
| Holder | Shares | Value |
|---|---|---|
| drw securities, llc | 27,136 | $8K |
Short Interest
as of May 20, 2026- % of float
- 2.7%
- Days to cover
- 3.9
- Shares short
- 141,010
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLSDQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. (CLSDQ) is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases, with one approved product (XIPERE) and a pipeline of suprachoroidal injection candidates.
What is Clearside Biomedical, Inc.'s next catalyst?
Clearside Biomedical, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA211950" — expected April 16, 2040.
Who is the CEO of Clearside Biomedical, Inc.?
Chief Executive Officer is the chief executive officer of Clearside Biomedical, Inc. (CLSDQ).
Where is Clearside Biomedical, Inc. headquartered?
Clearside Biomedical, Inc. (CLSDQ) is headquartered in Alpharetta, GA, United States.
What therapeutic areas does Clearside Biomedical, Inc. focus on?
Clearside Biomedical, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Ophthalmology, Dermatology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.